MISSION
Every day, we strive to eliminate the world’s
most devastating infectious diseases.
VISION
We envision a world where people live free
from the threat of infectious disease.
ABOUT SEATTLE BIOMED
Seattle Biomedical Research Institute (Seattle BioMed)
is the largest, independent, non-profit research institute
in the U.S. focused solely on the world’s most devastating
infectious diseases. More than 325 strong, we are dedicated
to reducing human suffering and saving lives by converting
knowledge into solutions.
Our research is the foundation for new vaccines, drugs
and diagnostics that will benefit those who need our help
most: the 14 million who will otherwise die each year from
infectious diseases.
DISEASE FOCUS
Emerging & Neglected Diseases
African sleeping sickness
Amebiasis
Chagas’ disease
Fungal infections
Leishmaniasis
Toxoplasmosis
HIV/AIDS
Malaria
Tuberculosis
307 Westlake Avenue North, Suite 500
Seattle, Washington 98109-5219 USA
Phone: 206.256.7200
Fax: 206.256.7229
seattlebiomed.org
© 2010 Seattle Biomedical Research Institute.
Printed on recycled paper.
2010 ANNUAL REPORT
SEATTLE BIOMEDICAL RESEARCH INSTITUTE
FREEDOM FROM INFECTIOUS DISEASE
From our founder who envisioned a new research environment to our scientists who create new ways to tackle age-old diseases, Seattle BioMed is inspired by the vision of a world free from infectious disease.
What’s Next?
360 Degree View
How do scientists determine which
Through a microscope lens and within
pathogens involves studying the immune cells and how they respond to infection,”
vaccine candidates to move to clinical
the patterns of gene sequences, scientists
said Nick Crispe, M.D., Ph.D., a malaria principal investigator whose area of
trials? Principal Investigator Helen Horton,
glimpse into the inner workings of cells.
expertise is immunology.
Ph.D., asked just this question. Her team
For 35 years, Seattle BioMed has asked
of researchers hopes to test a new in vitro
questions about pathogens that cause
vaccination model that will predict which
disease. What makes latent TB suddenly
HIV vaccines are likely to succeed in
activate? How can we stop malaria
human clinical trials.
parasites moving from the liver stage
“In vitro vaccination is basically a way to
replicate immune cell responses in a Petri
dish,” explains Horton. “This approach
allows us to see how human immune cells
will react to vaccines before testing them
Ken Stuart, Ph.D.
in more expensive preclinical models.”
The Visionary
Until recently, no one had used the in
Seattle BioMed President and Founder Ken Stuart, Ph.D., readily confesses that his
vaccine candidates. With support from
passion for understanding parasites and the diseases they cause fueled his move
a new grant awarded by the National
into a research area neglected by U.S. scientists in the mid-1970s.
Institutes of Health, Horton’s lab is using
More concerning to Stuart was the way research was being conducted. “The
landscape was dominated by academia and government labs,” he explained.
“Scientists worked in small groups and were primarily located at large, complex
vitro vaccination approach to test HIV
to understand how TB bacteria, for example, are able to evade the immune system,
we can develop strategies to circumvent it,” said Kevin Urdahl, M.D., Ph.D., a
principal investigator in Seattle BioMed’s TB Program.
looking at disease from the pathogen
perspective, Seattle BioMed scientists are
turning to immunology to sharpen our
focus on the host perspective, enabling
researchers to expand their view of
disease from 180 to 360 degrees.
“Understanding how a human or
animal host deals with invading
HIV that remain constant.
in research.”
is an extremely variable virus.
June 1976, Stuart’s vision became a reality.
Seattle BioMed is a place where this can happen. “If investigators can collaborate
that target specific regions of
The problem with HIV is that it
and scientifically nimble, as well as collaborative both internally and externally. In
closer to answering these questions by
work in close collaboration with virologists, bacteriologists and parasitologists.
this approach to test vaccines
organizations with limited capacity for adaptation to rapidly developing changes
Stuart envisioned a different type of organization – one that would be administratively
to the blood stream? While we’ve come
To effectively understand the host side of the equation, immunologists need to
“It can change quickly – much
faster than influenza virus, for
Our solutions will have a global impact,
helping everyone from people in
Seattle to children in Southeast Asia.
example,” said Horton. “It is
the non-variable parts of HIV
With a smile, Stuart says that Seattle BioMed might be his greatest experiment
that we’ll test in a vaccine. If
of all. Has the experiment he envisioned 35 years ago been successful? The
we can confirm that HIV vaccine
answer is “Yes, but….” Yes, it has been successful in centralizing research
candidates are effective in our in
capabilities and encouraging collaboration to accelerate science. Yes, it has
vitro studies, then we can push
been successful in raising awareness that scientific research is the first step in
forward testing in a more
improving global health.
efficient, less costly manner
“But,” said Stuart, “the experiment is still under way.” Each day we gain new
that will lead to our ultimate
knowledge that can lead to our ultimate vision – a world without infectious disease.”
goal – an HIV vaccine.”
HIV researchers Lynn Chen &
Vasudha Sundaravaradan, Ph.D.
FREEDOM FROM INFECTIOUS DISEASE
On the Offense
Ashley Vaughan, Ph.D., holds a football in his hand – an unlikely sight in
the middle of a malaria lab. Using the football as a stand-in for the human
liver, Vaughan offers insight into how the malaria parasite invades the liver.
In the complex malaria life cycle, Vaughan explains, the liver stage of the
disease presents a bottleneck that could be the best point of attack, and
Seattle BioMed researchers are launching an offensive.
Stefan Kappe, Ph.D., has developed a weakened whole organism vaccine
candidate aimed at the liver stage. The first generation vaccine candidate
was created by deletions of two genes, but Kappe hasn’t stopped there.
“We are already making significant advances in the development of nextgeneration attenuated vaccine strains,” he explained.
While malaria has been around thousands of years and the malariacausing parasite was discovered more than 100 years ago, the liver stage
of the disease is relatively new – discovered in 1948 – so there’s much
still to be learned.
Ruobing Wang, M.D., Ph.D., set her sights on finding the unique immune
responses to the parasite while in the liver. “We are identifying immune biomarkers of protection that could be used to select antigens for the development of effective subunit vaccines,” she explained. Meanwhile, Malcolm
Gardner, Ph.D., is developing in vitro tests to determine if experimental
drugs can kill the liver stage parasite.
While the ultimate goal is new drugs and vaccines, Kappe states it more
simply. “We want to create a situation where the parasites check into
the liver, but they never check out,” he said, with a laugh.
[continued]
From Vision
to Reality
Three years ago, Seattle BioMed
didn’t have a tuberculosis program,
and the lack of research focus on
that disease was a nagging issue in
Ken Stuart’s mind. Stuart formed a
task force to discuss the idea, and the
“It all started with an opportunity
Nick Hasle
Nick Hasle, an undergraduate at
Shahin Shafiani
Seattle BioMed’s scientists come
feedback was not encouraging. High
to participate in BioQuest Acad-
Oxford University, came home
to us from all around the world;
hurdles were identified, including
emy,” recalled Augustine Ajuogu
to Washington for a summer in-
many are from countries where
about his zeal for global citizen-
ternship at Seattle BioMed focused
the burden of disease is a daily
ship. BioQuest, an educational pro-
on infectious disease research. “I’ve
presence. That’s why Seattle
gram of Seattle BioMed, educates
always been fascinated with learn-
BioMed looks both locally and
high school students about the
ing how things work,” said Hasle.
internationally to train students
importance of scientific research
“As a child, my favorite book was
in infectious disease research. Sha-
the need for expensive specialized
facilities, funding for research support
and recruitment of key scientists. In
typical fashion, Stuart forged ahead.
He recruited a highly-regarded
researcher, David Sherman, Ph.D.,
to lead the program, and sought the
necessary funding. A major step came
Training magnifies the power of our vision.
in the form of a $5 million challenge
grant from the Paul G. Allen Family
and trains teens in college level
about how the body works. I read
hin Shafiani, originally from Iran,
Foundation, for equipment and re-
disciplines. “BioQuest’s focus on
the chapter called ‘What makes
participated in the Seattle-India
search projects. A state-of-the-art lab
global health gave me a reason to
us sick?’ over and over again. I’m
Joint Research Training Program,
study, a passion to work for and
compelled to look inside the micro-
which provides
a cause to stand for.”
scopic world and understand how
promising students with advanced
it operates.”
training in infectious disease
was constructed, which in turn helped
attract two more principal investigators, Christoph Grundner, Ph.D., and
Now studying biology and math
During his undergraduate
research. During his training, Shafi-
believes in a vision for the world
internship, Hasle worked along-
ani was mentored by Kevin Urdahl,
that is really no different from that
side scientists who investigate the
M.D., Ph.D., a world-renowned
ies. “Just as people need an alarm to
of Seattle BioMed: to enable oth-
pathogens causing African sleeping
immunologist. The two formed a
wake up, the latent form of tuberculo-
ers to envision a world where ev-
sickness, Chagas’ disease and
lasting partnership and recently
sis – found in one-third of the world’s
eryone has a better quality of life.
leishmaniasis. “Our goal was to
joined Seattle BioMed’s Tubercu-
population – requires a signal to
“When people are given power
understand how trypanosomes
losis Program. Side by side, Urdahl
move from latency to active disease,”
and an idea, they act,” Ajuogu
function so that we could identify
and Shafiani are working
explained Sherman. “Our research-
said. “And I see a future like no
drug targets,” Hasle explained.
to discover new TB vaccines.
ers have discovered how one ‘alarm
other, where people are empow-
“With this internship to draw
clock’ – a blast of fresh oxygen – stirs
ered to confront the challenges of
from, I can pursue new goals
Training Program gave me an
latent TB from its slumber. Providing
our time.”
equipped with experience that
opportunity to train with a brilliant
will add tremendous value to
immunologist and an excellent
my future.”
mentor,” said Shafiani, “and I feel
Kevin Urdahl, M.D., Ph.D.
And, there’ve already been discover-
Ashley Vaughan, Ph.D.
Augustine Ajuogu
new insight into what makes TB tick
is critical to developing faster-acting,
at Northwestern University, Ajuogu
“The Seattle-India Joint Research
an immense sense of gratitude to
more effective drugs.”
We train at every level – from high school
to postdoc – and teach from Seattle to
labs in India, Africa and beyond.
the program for the opportunity.”
Seattle BioMed Leaders
Grantors & Contractors
Board of Trustees
PRINCIPAL INVESTIGATORS
American Medical Association Foundation
Jerry Cangelosi, Ph.D., Affiliate Member
American Society of Microbiology
Dean Allen
Chief Executive Officer
McKinstry
Nick Crispe, M.D., Ph.D., Full Member
Amgen Foundation
Michal Fried, Ph.D., Assistant Member
Antigen Discovery, Inc.
Malcolm Gardner, Ph.D., Full Member
Bill & Melinda Gates Foundation
Christoph Grundner, Ph.D., Assistant Member
Burroughs Wellcome Fund
Helen Horton, Ph.D., Associate Member
The Doctor Ralph and Marian Falk Medical Research Trust
Stefan Kappe, Ph.D., Associate Member
Foundation for Innovative New Diagnostics (FIND)
Peter Myler, Ph.D., Full Member
Foundation for the National Institutes of Health
Marilyn Parsons, Ph.D., Full Member &
Director of Science Operations
Fred Hutchinson Cancer Research Center
David Sherman, Ph.D., Program Director & Full Member
Implicit Bioscience Ltd.
Joe Smith, Ph.D., Interim Program Director &
Associate Member
Infectious Disease Research Institute
Don Sodora, Ph.D., Associate Member
Leo Stamatatos, Ph.D., Program Director & Full Member
Imperial College of London
M.J. Murdock Charitable Trust
Gregg Blodgett
Chief Financial Officer
Twisted Pair Solutions
Jane Hedreen
Owner, Flora & Henri
Medicines for Malaria Venture
Ted White, Ph.D., Program Director & Full Member
Alan Levy, Ph.D.
CEO, Incline Therapeutics
Fogarty International Center
Neil McDonnell, Pharm.D.
Deputy Director of Strategy
Global Health Program
Bill & Melinda Gates Foundation
The Medtronic Foundation
National Center for Research Resources
National Heart, Lung, and Blood Institute
Jason Carnes, Ph.D.
National Institute of Allergy and Infectious Diseases
Amy DeRocher, Ph.D.
National Institute of Dental and Craniofacial Research
Sean Gray, Ph.D.
Bryan C. Jensen, Ph.D.
National Institute of Diabetes and Digestive
and Kidney Diseases
Henning Mann, Ph.D.
National Institute of General Medical Sciences
Sebastian Mikolajczak, Ph.D.
National Institute of Neurological Disorders and Stroke
Andrew V. Oleinikov, Ph.D.
Oregon Health and Science University
Brian G. Oliver, Ph.D.
PATH
Aswini Panigrahi, Ph.D.
Paul G. Allen Family Foundation
Tige Rustad, Ph.D.
Rhode Island Hospital
Noah Sather, Ph.D.
Science Applications International Corporation
George Sellhorn, Ph.D.
Silver Family Foundation
Angela Talley, M.D., Lead Trials Investigator
Special Libraries Association
Ashley Vaughan, Ph.D.
Stanford University
Marissa Vignali, Ph.D.
U.S. Army Medical Research and Materiel Command
U.S. Department of Health and Human Services - HRSA
VISITING SCIENTIST
U.S. Environmental Protection Agency
Patrick Duffy, M.D.
United States-Israel Binational Science Foundation
University of Pennsylvania
Todd Patrick
Chair
Community Volunteer
Greg Simon, J.D.
Senior Vice President, Worldwide Policy, Pfizer Inc.
Mike Stull
Treasurer
Chief Financial Officer, Clarisonic
Moya Vazquez
Community Volunteer
Emeritus Board
Melissa Yeager
Chief Operating Officer, Cardeas Pharma
Tom Blackwell, Director of Information Technology
Randy Hassler, Vice President of Operations & Finance
Kent Irwin, Director of Facilities
Michael Podlin, Vice President of Institutional Advancement
Lee Schoentrup, Director of Communications
Ken Stuart, Ph.D., President, Director & Founder
Jeanine Willis, Director of Human Resources
Lynn Zimmerman, Director of Finance
BIOQUEST
Theresa Britschgi, Director of BioQuest
2010
2010
Kris Richey
Vice President, Kinzer Real Estate Services
Bonnie Towne
Community Volunteer
Jilan Liu, M.D., M.H.A.
HIV/AIDS 16.5%
Investment and Other Income 6.7%
Erick Rabins
Chief Business Development Officer &
Senior VP, Strategic Affairs
C3-Jian, Inc.
Washington Global Health Alliance
Alan Alhadeff
Malaria
44.3%
Christopher H. Porter, Ph.D.
President, Medical Genesis
Jean Feagin, Ph.D.
MANAGEMENT
Government
Grants 47.9%
Trevor Moody
Vice Chair
President,
TM Strategic Advisors LLC
University of Washington
Rentala Madhubala, Ph.D.
Private Grants
& Contracts
44.3%
Emerging &
Neglected
Diseases
26.7%
Terrence R. Meersman
Vice President, Programs
Margaret A. Cargill Foundation
AFFILIATE SCIENTISTS
Alice Tarun, Ph.D.
Tuberculosis 12.5%
Marlyn Friedlander
Community Volunteer
Eunice Kennedy Shriver National Institute of
Child Health and Human Development
Achim Schnaufer, Ph.D.
Budget by Scientific Program Area
Contributions 1.1%
Maud Daudon
Immediate Past Chair
President & CEO
Seattle-Northwest Securities Corporation
Ruobing Wang, M.D., Ph.D., Associate Member
SENIOR & STAFF SCIENTISTS
Revenue & Support
Jane A. Biddle, Ph.D.
Technology Transfer Consultant
National Institutes of Health
Kevin Urdahl, M.D., Ph.D., Assistant Member
Fiscal years ending June 30 (dollars in thousands)
Rosemary Barker Aragon
Executive Director
Pacific Hospital Preservation & Development Authority
Darryl Johnson
Secretary
Former US Ambassador to Thailand & Lithuania
Ken Stuart, Ph.D., Full Member, President & Director
S E L E C T F I N A N C I A L D ATA
Statements of Financial Position
Cash & investments
2010
2009
$19,037,896
$23,194,705
$432,449
$1,874,506
$7,301,587
Pledges receivable
Other assets
Statements of Activities
2010
2009
Government grants
$23,723,086
$16,182,487
$5,717,821
Private grants
$21,915,452
$22,850,761
Support and revenue
COUNCIL OF SCIENTIFIC ADVISORS
Property and equipment
$10,934,896
$10,691,336
Contributions
$494,903
$4,209,148
Ben Shapiro, M.D., Chair
Director of Research, Retired
Merck Research Laboratories
Total assets
$37,706,828
$41,478,368
Educational program
$112,918
$332,914
Rafi Ahmed, Ph.D.
Director, Emory Vaccine Center
Emory University
Accounts payable and accrued expenses
$4,593,542
$5,848,727
Investment and other income
$3,228,851
$2,560,332
Advances and deferred obligations
$9,686,105
$10,036,088
Total support and revenue
$49,475,210
$46,135,642
Capital project debt
$3,481,384
$4,404,992
Total liabilities
$17,761,031
$20,289,807
$43,820,173
$38,687,302
Total net assets
$19,945,797
$21,188,561
$933,110
$980,808
$5,153,655
$4,189,915
$811,036
$694,378
Total expenses
$50,717,974
$44,552,403
Increase in net assets
($1,242,764)
$1,583,239
Margaret Allen, M.D.
Katherine M. Lombardo
Ellsworth Alvord Jr., M.D.
Gary McGlocklin
Mark Benjamin, Sc.D.
Peter Miller, J.D.
J. Paul Blake
Susan Morgensztern
Carol Bryan
Peggy Morrow
Vince Bryan
Thomas O’Rourke
Robert Bunting
Judy Pigott
Alice Burgess
Gloria Pfeif
John Creighton, Esq.
Thomas Ranken
Andrew Dale
Chuck Robertson
James Davie
Gilbert Scherer
Nancy Duncan
Ezra Teshome
Bruce Easter
Usha Varanasi, Ph.D.
Thomas E. Wellems, M.D., Ph.D.
Chief, Malaria Genetics Section
NIAID, NIH
Janet Lane Eaton
Tom Waldron
Updated Nov. 15, 2010
Steve Gillis, Ph.D.
Rick Weller, M.D., D.T.M.& H.
Harris Hoffman
Michelle A. Williams, Sc.D.
James A. Johnson
Mary Williamson
John King
James Woods, Ph.D.
Alvin Kwiram, Ph.D.
Jeffrey Wortley
Carol Lewis
Louis Yaseen
Clifton E. Barry, III, Ph.D.
Senior Investigator, Chief
Tuberculosis Research Section,
NIAID, NIH
John W. Shiver, Ph.D.
Vice President
Worldwide Basic Research Franchise Head
Vaccines Merck Research Laboratories
This is a publication of Seattle BioMed’s Communications
Department: Lee Schoentrup, director, and Jennifer
Mortensen, specialist. Photo credits: Severine Monnerat,
Jennifer Mortensen and Will Winslow.
Cover photo: Seattle BioMed scientists Anuradha Kumar,
Ph.D., and Meredith Heestand.
Expenses
Research program
Educational program
Management and administrative
Fundraising
Audited statements available upon request.
Please email [email protected].
A shared vision is
more powerful
Providing a pipeline of information
around the world, collaboration is
one of the keys to scientific discovery.
A Washington state-based collaboration
— the Seattle Structural Genomics
Center for Infectious Disease (SSGCID)
led by Seattle BioMed’s Peter Myler,
Ph.D. – helped shed new light on the
Influenza virus, showing that the recent
pandemic-causing H1N1 flu virus used a
biochemical “trick” to spread efficiently
in humans. The SSGCID uses state-ofthe-art high-throughput technology
to experimentally determine the threedimensional structures of proteins from
a number of bacterial, viral, fungal and
Moei River,
Thai-Burma
border
protozoan pathogens.
COLLABORATORS
Seattle BioMed’s David Sherman, Ph.D.,
and his team are playing a critical role
in a Stanford University partner-based
program in Systems Biology for Infectious
Disease Research. Employing the most
advanced high-throughput tools and
technologies, the project is developing
an iterative data-driven mathematical
model of TB bacteria responding to
stress. Sherman predicts results will
provide a new level of understanding
of how the disease works in humans.
With more than 100 collaborations with
leading organizations throughout the
U.S. and around the world, Seattle
BioMed has powerful partnerships
leading to new discoveries in the
Former Portuguese settlement “Ilha De
Moçambique”, North Mozambique
battle against infectious disease.
Quilaquila, Bolivia
INTERNATIONAL
UNITED STATES
Astellas Pharma Inc., Japan
Biomedical Primate Research Centre, The Netherlands
Christian de Duve Institute of Cellular Pathology (ICP),Université Catholique de Louvain (UCL), Belgium
Egerton University, Kenya
Griffith University, Australia
Guy’s Hospital, U.K.
Foundation for Innovative New Diagnostics (FIND), Switzerland
INOVIO, Norway
Institute of Parasitology, Czech Academy of Sciences, Czech Republic
Institute of Protein Biochemistry, National Research Council, Italy
International Center for Genetics and Biotechnology, India
International Centre for Diarrheal Disease Research, Bangladesh
Jawaharlal Nehru University, India
London School of Hygiene and Tropical Medicine, U.K.
McGill University, Canada
Morogoro Regional Hospital, Tanzania
Nanomics Biosystems Pty Ltd, Australia
National Institute of Infectious Diseases, Japan
National Institute for Medical Research, Tanzania
National Institute of Public Health and the Environment, The Netherlands
National Research Council, Canada
Norwegian University of Science and Technology (NTNU), Norway
Novartis Institute of Tropical Diseases, Singapore
Response Biomedical Corporation, Canada
Ruhr-Universität Bochum, Germany
Sokoine University, Tanzania
Pasteur Institute, France
TriTryp Genome Consortium
Tumaini University, Tanzania
Universitätsklinikum Charité Berlin, Germany
University of Antioquia, Colombia
University of Buea, Cameroon
University of Cambridge, U.K.
University of Capetown, South Africa
University of Copenhagen
and Rigshospitalet, Denmark
University of Dar es Salaam, Tanzania
University of Dundee, Scotland, U.K.
University of Edinburgh, Scotland
University of Glasgow, Scotland
University of Heidelberg, Germany
University of Nairobi, Kenya
University of Otago, New Zealand
Oxford University, U.K.
University of Queensland, Australia
University of the Ryukyus, Japan
University of the Witwatersrand, Johannesburg, South Africa
Unversidade Federal de São Paulo, Escola Paulista de Medicina, UNIFESP-EPM, Brazil
Vrije Universiteit, The Netherlands
Walter and Eliza Hall Institute of Medical Research, Australia
Wellcome Trust Sanger Institute, U.K.
Aaron Diamond AIDS Research Center
Bill & Melinda Gates Foundation
Blood Cell Storage, Inc.
Boston University
Brandeis University
Broad Institute
Brown University Medical School
Buck Institute
C3 Jian, Inc., Los Angeles
California Institute for Medical Research
California Institute of Technology
California National Primate Research Center
Centers for Disease Control & Prevention (CDC)
Columbia University
Cornell University
Drexel University
Duke University
Fred Hutchinson Cancer Research Center
Haborview Medical Center
Harvard University
ImmPORT Therapeutics, Inc.
Indiana University
Infectious Disease Research Institute
Institute for Systems Biology
Johns Hopkins University
La Jolla Institute of Allergy and Immunology
Los Alamos National Laboratory
Merck Research Laboratories
Microsoft Research
National Institutes of Health
New York University
North Carolina State University
Northwestern University
Novartis
Oregon Health & Science University
Oregon National Primate Research Center
Oregon State University
PATH
Pacific Northwest National Laboratory
Portland Veterans Affairs Medical Center
Rosetta/Merck Research Labs
Saint Louis University
Santa Clara Valley Medical Center
Schering Plough Biopharma
Scripps Research Institute
Seattle Genetics
Southwest National Primate Research Center, San Antonio
Stanford University
TB Control Program, Public Health - Seattle-King County
Texas A & M University
Tulane National Primate Research Center
Tulane University
University of California, Berkeley
University of California, Davis
University of California, Los Angeles
University of California, San Francisco
University of Chicago
University of Illinois, Chicago
University of Iowa
University of Massachusetts, Worchester
University of Michigan
University of Missouri
University of Nebraska
University of North Carolina
University of Oklahoma
University of Oregon
University of Pennsylvania
University of Pittsburgh
University of Rochester Medical Center
University of San Diego
University of Texas, San Antonio
University of Virginia
University of Washington
U.S. Environmental Protection Agency
Vanderbilt University
J. Craig Ventner Institute
Walter Reed Army Institute of Research
Washington National Primate Research Center
Yale University
Yerkes National Primate Research Center, Atlanta
Thank You for Bringing Our Vision to Life
The most influential visionaries are people just like you – citizens of the world who
contribute time, money and voices to improve global health. The individuals, foundations
and corporations that share our vision of a world free from the threat of infectious disease
enable Seattle BioMed to expand innovative research programs, recruit bright scientists
and form powerful alliances that advance solutions to malaria, HIV/AIDS, TB and
other neglected diseases.
Imagine a world where people are healthy. There would be less poverty and fewer
orphans. There would be stronger economies and more stable societies. There would
be hope. Thank you for helping us turn this vision into reality by supporting the discovery
of diagnostics, drugs and vaccines that can ultimately benefit hundreds of millions of
people every year. Visit seattlebiomed.org/breakthrough-fund to learn more.
Founder’s Circle
$250,000+
Bill & Melinda Gates Foundation
$50,000+
Dean & Vicki Allen/McKinstry Co.
Charitable Foundation
Lease Crutcher Lewis
Silver Family Foundation
$25,000+
Anonymous
Byron & Alice Lockwood Foundation
$10,000+
The Paul G. Allen Family Foundation
Amgen Foundation
Anonymous
James & Holly Johnson
KeyBank National Association
Gloria Pfeif
Gilbert Scherer & Marlyn Friedlander
Charles Spear Charitable Trust
Cory Van Arsdale & Melissa Yeager
Vulcan Inc.
Pacesetters’ Circle
$5,000+
Anonymous
Maud & Marc Daudon
Tom & Joanne Erlandson
Firland Foundation
David & Amy Fulton
Gilead Sciences, Inc.
Richard & Elizabeth Hedreen
Kinzer Real Estate Services
Mark Malamud & Susan Hautala
Todd & Julie Patrick
Mary Pigott
Lucie Robitaille & Antoine Leblond
David Thyer & Jane Hedreen
We Work For Health
The Adam J. Weissman Foundation
Wells Fargo Insurance Services
Northwest, Inc.
$2,500+
Zoe, Zan & Sasha Barker-Aderem
Alexandria Real Estate Equities Inc.
Mari Anderson & Terry Green
Anonymous (2)
Kristin & Steven Beaulieu
Jane A. Biddle, Ph.D. & Kenneth B.
Seamon, Ph.D.
Gregg & Jane Blodgett
BNBuilders, Inc.
Brian & Rebecca Butler
Clete & Bronwen Casper
ClearPoint, LLC
James & Sarah Davie
Bruce Easter & Cynthia Faubion
Barry & JoAnn Forman
Matt Griffin & Evelyne Rozner
Lars Jonsson & Laurie McDonald
Jonsson
Trevor J. Moody & Laura Hernon
Moss Adams LLP
O’Keefe Family Foundation
Petrizzo Strategic Group, Inc.
Michael Podlin
Christopher & Kathryn Porter
Lawrence J. Roseman
Sabey Corporation
Rajeev Singh
Drs. Ken Stuart & Julie McElrath
VLST Corporation
Moya Vazquez
Nanette & Will Welton
Jeanine Willis & Eric Freyberg
ZymoGenetics, Inc.
$1,000+
John Aitchison
Nancy Alvord
Rob Angel
Anonymous (2)
Perry & Christine Atkins
David & Madeleine Brenner
Gregory Chan
Clark Nuber P.S.
Sally Collins & Chris Warth
Paul & Debbie Cressman
Barney Ebsworth
Deborah Elvins
Carolynn & Hal Ferris
Greg & Shalisan Foster
Kerry Fowler & Jan Gray
Maureen Frisch
Saul Gamoran & Gurline Baptiste
Malcolm J. Gardner & Ruobing Wang
William & Mimi H. Gates, Sr.
Greg & Val Gorder
Randy & Melanie Hassler
Scott & Emily Highleyman
Hudson Bay Insulation
Keith & Kuma Ito
Darryl & Kathleen Johnson
Pam & Kim Kaiser
Janet Ketcham
Irene & Timothy Kilgallon
Alan & Sharon Levy
Carol Lewis & Tom Byers
Neil & Merri Ann McDonnell
Peter Miller & Jean Johnson
Susan & Isaac Morgensztern
Charles & Eleanor Nolan
PATH
Drs. Ettore & Setareh Palazzo
Morningside Foundation
Dana Pigott
Judy Pigott
William Pope & Teresa Castner
Paul & Julie Pottinger
Regina Rabinovich
Erick & Marta Rabins & Family
Gordon & Gretchen Raine
Robert & Virginia Rausch
Thurston & Catherine Roach
The Reuben B. Robertson Foundation
Genie Sheth
Brad & Michele Smith
Jay Sorensen
Margaret & Hunt Stockwell
Mike & Sandra Stull
Daniel D. Syrdal
Lyn Tangen & Dick Barbieri
Ezra & Yobi Teshome
John & Teresa Tippett
University of Washington Global
Business Center
Dr. Theodore & Iris Wagner
Janet & John Walker
Washington Global Health Alliance
Doug & Ann Williams
Mary Williamson & Kurt Kiefer
Chris Wilson
Richard & Katherine Wolniewicz
Edward & Marcy Yoshida
Mariann & Kirk Zylstra
Supporters
$500+
Anonymous (4)
Bruce & Joann Amundson
Rosemary Barker Aragon
Michael & Debra Birt
Tom Blackwell
Karen Blöchlinger
Ann Bradford & Geoff Patterson
Robert & Theresa Britschgi
Fred & Jane Buckner
Victoria Buker
Randy Campadore
Joe & Sara Cerrell
Melissa Corvelli
Wanda A. Current
Carol Dahl
Earl & Anita Davie
David & Katherine De Bruyn
Cynthia Hartwig & Tom Booster
John & Vicki Haskell
Karen M. Hill & Sheldon N. Rosen
Kathryn Hinsch
David Humphries & Michelle
McCarthy
Richard & Andrea Hutton
Kent & Louise Irwin
Karen Jones & Erik Rasmussen
Kevin & Jean Kelly
Hans & Kelly Kemp
ChiEun Kim
Michael Kimerling & Anne Dumoulin
Daniel Kress & Patricia Glick
Laird Norton Tyee
Roy & Susan Mann
Terry Meersman & Carmen de la Hoz
Scott & Melissa Milburn
Grayce & Rob Mitchell
Nicole & Robert Mooney
Eileen & Barry Murphy
Shirley Naganawa & Gary Kawasaki
H. Stewart Parker
Paul & Cynthia Parker
Marilyn Parsons
Molly Pengra
Anne Pfeif
Patricia Pfeif
Audi Purnaveja
Kris Richey
Dr. Mack & Susan Richey
Jeffrey Ried
Renee Ridzon
Steve Romein & Ty Cramer
Stephen Rothrock & Tessa Keating
James & Joy Roush
Mary Jean Ryan
Susan Scanlan & Anthony Lo
Mig Schaaf & Stuart Dunwoody
Will & Lee Schoentrup
Tim Schottman
Schultz Miller
Sellen Construction
Walter & Patricia Shea
David Sherman
Susan Sigl
Todd & Carolyn Simpson
Don Sodora
Leo Stamatatos & Tina de Jong
Sandhya Subramanian
Claire Topal
Maria Vasilakis
David & Lolly Victor
Doug & Stacey Waddell
Ted White, Ph.D.
Drs. Tad & Morgan Whiteside
Marion Woodfield & Marc Weinberg
Scott Wyatt
Tachi & Leslie Yamada
$250+
Susan Adler
Theodore & Cynthia Anderson
Anonymous (10)
Barbara Nordfors
Teresa Bigelow & Eric Larson
Curt Blake & Kelli Curtis
Elisabeth Bodal
Zan Brookshire & Bert Green
Alan Brown & Peo Gudmundsson
Evan Brown
Erik Busse’
Peter Carpenter
Jennifer Cohen
Tom & Lisa Cohen
Sue Coliton
Raymond & Anita Connell
Jeff Coopersmith, Esq. & Lisa
Erlanger
Janice Culpepper
Peter Danelo
Richard Dodd
Jennie Dodson
Jim & Amos Edwards
Shelby Edwards
Steve Eirschele
Dr. Carl & Bonnieclare Erling
Anson W. Fatland
Don Forbes & Jean Brittingham
Michal Fried
Christopher Gardner & Lynn Jones
Lisa George
Tim & Chitra Hanstad
Randall & Stefanie Hargreaves
Joe & Denise Harris
Peter Harris
Michael & Alicia Hatch
Ada Healey
Betsy Hentz
Paul & Jan Hess
Frederick & Gloria Hoedemaker
Arthur E. Holtz
Helen Horton & Donald Carter
Ashley Hulsey & Marc Kittner
Lee Huntsman
Elizabeth James
Maryellen Johnson & Huw Davis
Patrick Johnson
Kathleen F. Joncas
Tom Kanyok
Diane Grove & Mark Kibbey
Deborah Kolp
Michael Kreis & Cathryn
Vandenbrink
Art Langlie
Alice Lin
Scott Lipsky
Susannah Malarkey
Jeff Marcell
George & Beverly Martin
Nancy & John B. McClane
Nate Miles
Kiran Mir
Tracy Mitchell
R. Moritz
Peggy Morrow
Jennifer & Mikael Mortensen
MSNBC.COM
Marie Neumann
Lori Noto
Rodney Hearne & Roger Nyhus
Phyliss Nelson
David Palus
David Park
Ken & Carol Pawlak
Tom & Amy Payne
Riley & Nancy Pleas Family
Foundation
John & Katarina Powell
Sally Quy
Renee Ridzon
Scott & Kerry Rosenkranz
Brock Russell
Marlys Sage
Sidiya Schoppert
Peter & Mary Schroeder
Scott E. Shapiro
Carol Sibley, Ph.D.
Joseph & Leia Smith
Marian Smith
Zachary Smith
Dale Sperling
Amanda & Brent Spraker
Jill Summit
Craig Tall
Angela Talley & Marc Greilsamer
Sherilyn Anderson Tan & David Tan
Preston Thompson
Jena Thornton
David Tutt
John Vadino
Dave Weaver
Kathy Wehle & Theresa Haynie
Katherine Weybright
Yang Zhang
Lynn Zimmerman & Jim Benbow
The 2010 donor list includes new pledges, outright gifts of cash and stock, pledge payments,
and in-kind donations received from July 1, 2009, through June 30, 2010. Donors of $1,000
and above are listed on the donor wall at Seattle BioMed.
Each of our donors is important to us. Please email [email protected] with any
omissions or errors.